Citi raised the firm’s price target on Royalty Pharma (RPRX) to $42 from $40 and keeps a Buy rating on the shares as part of a Q2 earnings preview for the biotechnology group. The firm says Q2 is typically seasonally strong for the large biopharma names.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma Strengthens Board with New Appointments
- Royalty Pharma appoints Ho, Weatherman to board of directors
- Royalty Pharma price target raised to $54 from $51 at Morgan Stanley
- Strategic Financial Agreements and Promising Drug Developments Justify Buy Rating for Royalty Pharma
- Royalty Pharma’s Strategic Partnership with Revolution Medicines: A High-Reward Investment Opportunity